Sanofi, Regeneron put potential $5B in sales on the horizon with new PhIII dupilumab data

Partners Sanofi ($SNY) and Regeneron ($REGN) now have data in hand proving their atopic dermatitis candidate drug dupilumab can top placebo in clearing skin, reducing itching, and upping quality of life and mental health. The next step? Putting that data in to a regulatory package that the pair intends to submit to the FDA in the third quarter of this year. And if regulators are game, some optimistic analysts predict annual sales could soar up to $5 billion per year. More from FiercePharmaMarketing

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.